News
CRMD
5.56
+2.21%
0.12
CVAC, SBNY and CRMD are among after hour movers
On the Move CVAC, SBNY and CRMD are among after hour movers. Vanda Pharmaceuticals and Sutro Biopharma are among the companies to gain. Eton Pharmaceuticals, Leslie's and Signature Bank are among those to lose. The day's top 10 stocks.
Seeking Alpha · 1d ago
CORMEDIX INC. ANNOUNCES U.S. INPATIENT COMMERCIAL AVAILABILITY OF DEFENCATH® (TAUROLIDINE AND HEPARIN)
Reuters · 3d ago
Weekly Report: what happened at CRMD last week (0408-0412)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Qilian Intl Hldg Gr (NASDAQ:QLI) stock moved upwards by 50.4% to $1.14 during Friday's after-market session. Allarity Therapeutics stock rose 18.09% and Galecto stock increased by 5.58%. PaxMedica stock declined by 8.0% during the session.
Benzinga · 6d ago
Wall Street Analysts Predict a 146.21% Upside in CorMedix (CRMD): Here's What You Should Know
NASDAQ · 04/11 13:55
CorMedix Price Target Maintained With a $19.00/Share by JMP Securities
Dow Jones · 04/09 12:50
JMP Securities Reiterates Market Outperform on Cormedix, Maintains $19 Price Target
Benzinga · 04/09 12:39
Truist Financial Remains a Buy on Cormedix (CRMD)
TipRanks · 04/09 11:35
Understanding Analyst Recommendation Reports: A Comprehensive Summary
TipRanks · 04/09 10:05
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Shandong Weigao Group Medical Polymer Co (OtherSHWGF) and Cormedix (CRMD)
TipRanks · 04/09 04:30
CorMedix enters into 5-year agreement with ARC Dialysis
Healthcare CorMedix enters into 5-year agreement with ARC Dialysis. CRMD expects to begin the commercialization of DefenCath in the inpatient setting on April 15th. The company has entered into a commercial supply contract with the Florida-based dialysis provider.
Seeking Alpha · 04/08 12:54
CorMedix Inc. Announces 5-Year Contract With Dialysis Provider, ARC Dialysis For The Supply Of DefenCath
CorMedix has entered into a 5-year commercial supply contract with Florida-based dialysis provider, ARC Dialysis, LLC for the supply of defenCath. DefenCath is the first-and-only FDA-approved antimicrobial catheter lock solution. The company expects to begin commercialization of the product in the inpatient setting in April.
Benzinga · 04/08 12:41
CORMEDIX INC: 5-YEAR COMMERCIAL SUPPLY CONTRACT WITH ARC DIALYSIS, LLC FOR SUPPLY OF DEFENCATH (TAUROLIDINE AND HEPARIN)
Reuters · 04/08 12:30
Weekly Report: what happened at CRMD last week (0401-0405)?
Weekly Report · 04/08 10:50
CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC
CorMedix Inc. Has entered into a 5-year commercial supply contract with Florida-based dialysis provider, ARC Dialysis, LLC for the supply of DefenCath. The company is a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases.
Barchart · 04/08 07:30
Weekly Report: what happened at CRMD last week (0325-0329)?
Weekly Report · 04/01 10:48
Weekly Report: what happened at CRMD last week (0318-0322)?
Weekly Report · 03/25 10:50
Cormedix: Statement of changes in beneficial ownership of securities
Press release · 03/20 22:04
Weekly Report: what happened at CRMD last week (0311-0315)?
Weekly Report · 03/18 10:49
CorMedix Is Maintained at Outperform by RBC Capital
Dow Jones · 03/13 15:07
More
Webull provides a variety of real-time CRMD stock news. You can receive the latest news about Cormedix through multiple platforms. This information may help you make smarter investment decisions.
About CRMD
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.